New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
10:02 EDTMYL, COTY, NMBL, EGHT, TEX, O, CQP, JAH, WWAV, RGP, TCO, PRGO, AGN, ACMP, BIN, TEVA, SGNT, AKRX, ANIP, ACT, ACRXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ANI Pharmaceuticals (ANIP) initiated with a Buy at Roth Capital... AcelRx (ACRX) initiated with an Outperform at RBC Capital... Actavis (ACT) initiated with an Outperform at RBC Capital... Akorn (AKRX) initiated with an Outperform at RBC Capital... Allergan (AGN) initiated with an Outperform at RBC Capital... Cheniere Energy Partners (CQP) initiated with an Outperform at Credit Suisse... Mylan (MYL) initiated with an Outperform at RBC Capital... Perrigo (PRGO) initiated with a Top Pick at RBC Capital... Realty Income (O) initiated with an Outperform at Oppenheimer... Sagent Pharmaceuticals (SGNT) initiated with an Underperform at RBC Capital... Taubman Centers (TCO) initiated with a Perform at Oppenheimer... Terex (TEX) initiated with a Hold at Jefferies... Teva (TEVA) initiated with a Sector Perform at RBC Capital... Regency Energy Partners (RGP) reinstated with an Outperform at Credit Suisse... 8x8, Inc. (EGHT) initiated with a Buy at Needham... Progressive Waste (BIN) initiated with an Underperform at Macquarie... WhiteWave Foods (WWAV) reinstated with an Overweight at JPMorgan... Nimble Storage (NMBL) initiated with a Buy at Stifel... Access Midstream (ACMP) coverage assumed with an Outperform at Credit Suisse... Jarden (JAH) initiated with an Outperform at RBC Capital... Coty (COTY) initiated with a Sector Perform at RBC Capital.
News For ANIP;ACRX;ACT;AKRX;AGN;CQP;MYL;PRGO;O;SGNT;TCO;TEX;TEVA;RGP;EGHT;BIN;WWAV;NMBL;ACMP;JAH;COTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
July 22, 2015
10:06 EDTPRGO, MYL, TEVAAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
09:50 EDTCQPCheniere Energy Partners LP initiated with an Accumulate at Global Hunter
Target $35.
09:30 EDTTEVA, MYLAbbott CEO says 'pretty alligned' with Mylan so far
07:14 EDTPRGOPerrigo agrees to acquire Yokebe
Subscribe for More Information
July 21, 2015
14:24 EDTNMBLEarnings Watch: EMC reports amid M&A speculation in sector
Subscribe for More Information
10:01 EDTJAH, COTY, AKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:54 EDTAKRXAkorn initiated with a Neutral at Susquehanna
Subscribe for More Information
July 20, 2015
16:46 EDTCOTYCoty initiated with a Neutral at Sterne Agee CRT
Subscribe for More Information
16:35 EDTJAHJarden initiated with a Buy at Sterne Agee CRT
Target $61.
10:26 EDTTEVALeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
10:13 EDTCOTYOptions with decreasing implied volatility
Subscribe for More Information
08:38 EDTMYLAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTMYLInternational AIDS Society to hold a conference
Subscribe for More Information
07:30 EDTMYLZoetis 'highly likely' to merge with Bayer unit in 2016, says Jefferies
Subscribe for More Information
07:05 EDTAGNAllergan Q2 to alleviate competitive concerns, says JPMorgan
Subscribe for More Information
July 17, 2015
10:05 EDTAGNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Accretive Health (ACHI) downgraded to Market Perform from Outperform at Cowen... Allergan (AGN) downgraded to Outperform from Top Pick at RBC Capital... Best Buy (BBY) downgraded to Underperform from Buy at BofA/Merrill... Cablevision (CVC) downgraded to Hold from Buy at Jefferies... Credit Suisse (CS) downgraded to Hold from Buy at Deutsche Bank... Domino's Pizza (DPZ) downgraded to Sector Weight from Overweight at KeyBanc... First Quantum Minerals (FQVLF) downgraded to Neutral from Outperform at Credit Suisse... First Republic (FRC) downgraded to Market Perform from Outperform at FBR Capital... Fresenius SE (FSNUY) downgraded to Neutral from Buy at Goldman... Golden Minerals (AUMN) downgraded to Neutral from Buy at Roth Capital... JD Wetherspoon (JDWPY) downgraded to Reduce from Neutral at Nomura... NV5 Holdings (NVEE) downgraded to Neutral from Accumulate at Global Hunter... National Oilwell (NOV) downgraded to Sell from Neutral at UBS... Natural Gas Services (NGS) downgraded to Neutral from Buy at Global Hunter... Primoris (PRIM) downgraded to Neutral from Accumulate at Global Hunter... Receptos (RCPT) downgraded to Hold from Buy at Evercore ISI... SKF AB (SKFRY) downgraded to Hold from Buy at Deutsche Bank... STAG Industrial (STAG) downgraded to Sell from Neutral at UBS... SolarWinds (SWI) downgraded to Hold from Buy at Deutsche Bank... Syntel (SYNT) downgraded to Market Perform from Outperform at William Blair... TECO Energy (TE) downgraded to Neutral from Buy at UBS... Tangoe (TNGO) downgraded to Underweight from Equal Weight at Barclays... Tegna (TGNA) downgraded to Hold from Buy at Evercore ISI.
08:38 EDTMYL, PRGO, TEVALeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
07:25 EDTAKRXAkorn risk/reward favorable into restatements, says JPMorgan
Subscribe for More Information
06:39 EDTAGNAllergan downgraded to Outperform from Top Pick at RBC Capital
RBC Capital downgraded Allergan to Outperform and maintained its $361 price target. The firm sees few catalysts and is less confident near-term in P&L upside, but has left estimates unchanged. RBC Capital said there are several important products subject to competitive threats that could pressure sentiment but said valuation remains attractive against solid mid-teens multi-year earnings growth.
06:11 EDTJAHJarden 16M share Secondary priced at $54.50
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use